Lowered expression of microRNA-125a-5p in human hepatocellular carcinoma and up-regulation of its oncogenic targets sirtuin-7, matrix metalloproteinase-11, and c-Raf

Nicola Coppola1, Giorgio de Stefano2, Marta Panella3, Lorenzo Onorato1, Valentina Iodice2, Carmine Minichini1, Nicola Mosca3, Luisa Desiato3, Nunzia Farella2, Mario Starace1, Giulia Liorre2, Nicoletta Potenza3, Evangelista Sagnelli1, Aniello Russo3

1Department of Mental Health and Public Medicine, Second University of Naples, Naples, Italy
2IX Interventional Ultrasound Unit for Infectious Diseases, AORN dei Colli, P.O. Cotugno, Naples, Italy
3Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, Second University of Naples, Naples, Italy

Correspondence to: Aniello Russo, email: aniello.russo@unina2.it

Keywords: microRNA, gene regulation, cell proliferation, tumor, hepatocellular carcinoma

Received: November 08, 2016 Accepted: February 07, 2017 Published: February 28, 2017

Copyright: Coppola et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Human microRNA-125a-5p (miR-125a) is expressed in most tissues where it downregulates the expression of membrane receptors or intracellular transductors of mitogenic signals, thus limiting cell proliferation. Expression of this miRNA generally increases with cell differentiation whereas it is downregulated in several types of tumors, such as breast, lung, ovarian, gastric, colon, and cervical cancers, neuroblastoma, medulloblastoma, glioblastoma, and retinoblastoma. In this study, we focused on hepatocellular carcinoma and used real-time quantitative PCR to measure miR-125a expression in 55 tumor biopsies and in matched adjacent non-tumor liver tissues. This analysis showed a downregulation of miR-125a in 80% of patients, with a mean decrease of 4.7-fold. Comparison of miRNA downregulation with clinicopathological parameters of patients didn’t yield significant correlations except for serum bilirubin. We then evaluated the expression of known targets of miR-125a and found that sirtuin-7, matrix metalloproteinase-11, and c-Raf were up-regulated in tumor tissue by 2.2-, 3-, and 1.7-fold, respectively. Overall, these data support a tumor suppressor role for miR-125a and encourage further studies aimed at the comprehension of the molecular mechanisms governing its expression, eventually leading to treatments to restore its expression in tumor cells.

INTRODUCTION

Primary liver cancer is the fifth most common cancer in men and the ninth in women, with 554,000 and 228,000 new cases per year, respectively. In addition, it is the second most common cause of death for cancer worldwide, estimated to be responsible for nearly 750,000 deaths per year, i.e., 9% of all cancer deaths [1]. Hepatocellular carcinoma (HCC) is the predominant type of primary liver cancer and arises mostly in cirrhotic livers [2]. Since a few therapeutic options exist, particularly in the more advanced stages that require a systemic treatment, there is an urgent need for new biomolecular markers for an early diagnosis and of new therapeutic targets to improve the survival rate of patients with HCC.

MicroRNAs (miRNAs) are small non-coding RNAs that negatively regulate gene expression at post-transcriptional level by affecting both translation and stability of complementary mRNAs [3]. MiRNAs are involved in a large variety of physiological processes playing crucial roles in cell differentiation and development [4, 5]. Several studies have also shown that aberrant expression of miRNAs is linked to pathological conditions, including cancer [6]. Downregulation of the microRNA biosynthesis enzyme Dicer in cancer cells or mutations affecting its structure lead to dysregulated
miRNA biogenesis and increased tumor progression [7–10]. On the other hand, differentiating cells often exhibit increased Dicer expression [11–13]. In this field, a growing body of evidence indicates that miRNAs can function as either tumor suppressors by down-regulating oncogenic proteins, or tumor promoters by limiting the expression of oncosuppressor genes [14–16]. In HCC, miR-122 and miR-199a are frequently downregulated, suggesting a tumor suppressor role whereas miR-21 and miR-221 are often hyperexpressed [17–19]. Sorafenib is the only therapeutic agent for treatment of advanced HCC [20, 21] and a recent study has shown that miR-125a is a downstream effector of the drug in its antiproliferative activity toward carcinoma cells [22]; other microRNAs may also be involved in the mechanism of action of the drug [23].

MiR-125a regulates the expression of several genes controlling cell proliferation, migration, and apoptosis [24]. In the human breast cancer cell line SKBR3, tyrosin kinase receptors ERBB2 and ERBB3 are downregulated by miR-125a leading to diminished cell proliferation and migration [25]. This finding is corroborated by in vivo studies showing that miR-125a and -125b are downregulated in ERBB2-amplified and ERBB2-overexpressing breast cancers [26]. In several breast cancer cell lines, miR-125a also targets HuR, an RNA-binding protein that stabilizes transcripts of genes regulating cell proliferation, angiogenesis, rapid inflammatory response and stress response [27]. Overall, these data indicate that miR-125a may counteract proliferation and invasion of breast cancer cells through the downregulation of ERBB2, ERBB3, and/or HuR. These conclusions are also supported by the discovery of a germline mutation in the sequence of mature miR-125a that is highly associated with development of breast cancer [28].

A tumor suppressive role for miR-125a is also supported by a study performed in the human neuroblastoma SK-N-BE cell line [29]. MiR-125a was found to downregulate the truncated isoform of the neurotrophin receptor tropomyosin-related kinase C (t-trkC), with subsequent inhibition of cell proliferation. This finding is consistent with the observed underexpression of miR-125a in human primary neuroblastomas. MiR-125a is also down-regulated in other tumors, such as medulloblastoma [30], glioblastoma [31], and lung cancer [32] where it suppresses cell proliferation by targeting Zbtb7a proto-oncogene [33].

In HCC Hep3B and SNU-449 cells, miR-125a inhibits cell proliferation through the down-regulation of sirtuin-7 (SIRT7), a NAD(+)-dependent deacetylase, and subsequent p21-dependent cell cycle arrest in G1 [34]. This activity has recently been confirmed in HepG2 and HuH-7 cells [22]. In HCC, miR-125a is also known to target vascular endothelial growth factor A (VEGF-A), and matrix metalloproteinase-11 (MMP11) [35].

In this study, we contributed to the characterization of the tumor suppressive activity of miR-125a by measuring its expression in HCC biopsies and in matched adjacent non-tumor liver tissues and by correlating the obtained data with clinical presentation. The expression levels of validated targets of miR-125a were also determined.

RESULTS

Characteristics of patients

At the end of the enrollment period, 55 consecutive patients were included in the study. Their demographic, biochemical, virological, and clinical characteristics are summarized in Table 1. The mean age was 70.3 years, 32 (58.1%) patients were males, and 41 (74.5%) were anti-HCV positive with 33 (80.5%) of them showing detectable plasma HCV-RNA. HBV was identified as the etiologic agent of the disease in 10 (17.5%) patients and the remaining 4 (7.3%) had a NASH-related cirrhosis. Two patients had a history of alcohol abuse, both anti-HCV/HCV RNA positive; no other patients had a multiple etiology. Most of patients showed a compensated liver disease, with a Child-Pugh class-A in 89.1% of cases and classes-B/C in 10.9%. 27 (49.1%) patients showed an unifocal and 28 (50.9%) a multifocal HCC. According to the Barcelona Clinic Liver Cancer (BCLC) class, 47 (85.4%) had class A, 5 (9.1%) class B and 3 (5.5%) class C. Three patients showed also portal thrombosis.

Down-regulation of miR-125a in hepatocellular carcinoma

Real-time qPCR was used to measure the amount of miR-125a in HCC biopsies from 55 patients with viral hepatitis or NASH. Comparison with the adjacent non-tumor liver tissue (NC) revealed a down-regulation of the miRNA in 44 out of 55 patients (80%) (Figure 1), with a mean decrease of 4.7-fold. When the absolute amounts of the miRNA were considered, the mean content in HCC was 48% of that in NC and difference was highly significant (Figure 2). When patients were grouped based on HCC etiology, downregulation of the miRNA was detected in 8 out of 10 HBV patients (80%), 32 out of 41 HCV patients (78%), and 4 out of 4 patients with NASH. Down-regulation was statistically significant in each group and prominent in HCV patients whose expression of miR-125a was reduced to 45 % (Figure 3). This result was confirmed even when HCV-RNA positive (3.83±3.14 vs. 7.39±4.64 AU, p=0.0005) and HCV-RNA negative patients (4.78±3.81 vs. 10.3±5.01 AU, p=0.027) were separately analyzed.

Correlation between down-regulation of miR-125a in HCC and clinical characteristics

One of the aims of the study was to correlate the expression profile of miR-125a-5p in neoplastic and non neoplastic tissue and the clinical characteristics
of the subjects enrolled. When patients were stratified according to age, gender, transaminase levels, Child-Pugh score, BCLC score or other clinical characteristics of HCC (Table 2), no difference was observed between the mean fold-regulation of the miRNA in HCC vs. NC tissue. However, patients with total bilirubin serum concentrations higher than 1.1 mg/dL showed a markedly lower fold-regulation (-6.72±6.5 vs -1.84±2.63, p=0.02)) of the miRNA and no patient had a Gilbert’s syndrome.

Table 1: Demographic, biochemical, virological, and clinical characteristics of the enrolled patients

| Characteristic                                | Value          |
|-----------------------------------------------|----------------|
| N° patients                                   | 55             |
| Mean age (±SD)                                | 70.3 (6.0)     |
| Males, n° (%)                                 | 32 (58.1)      |
| Alcohol abusers (> 30g/die), n° (%)           | 2 (3.6)        |
| BMI (mean ± SD)                               | 26.8 (3.1)     |
| Subjects with diabetes, n° (%)                | 7 (12.7)       |
| AST/ULN (mean ± SD)                           | 1.54 (0.9)     |
| ALT/ULN (mean ± SD)                           | 1.49 (0.9)     |
| ALP/ULN (mean ± SD)                           | 1.12 (0.6)     |
| Total bilirubin, mg/dl (mean ± SD)            | 0.98 (0.5)     |
| PT% (mean ± SD)                               | 89.2 (12.8)    |
| α-fetoprotein, (mean ± SD)                    | 233.8 (713.4)  |
| Anti-HCV-positive patients, n° (%)            | 41 (74.5)      |
| - HCV-RNA-positive subjects, n° (%)           | 33 (80.5)      |
| - HCV load, IU/mL (mean ± SD)                 | 1.2 E+6 (1.68 E+6) |
| - with HCV-genotype 1, n° (%)                 | 28 (68.3)      |
| - with HCV-genotype non-1, n° (%)             | 6 (14.6)       |
| HBsAg-positive patients, n° (%)               | 10 (17.5)      |
| - HBV-DNA-positive subjects, n° (%)           | 3 (30.0)       |
| - HBV load, IU/mL (mean ± SD)                 | 1.13 E+4 (1.91 E+4) |
| Patients with NASH, n° (%)                    | 4 (7.3)        |
| Child Pugh score, n° (%) of patients with     | 55             |
| - A                                           | 49 (89.1)      |
| - B                                           | 6 (10.9)       |
| - C                                           | 0 (0.0)        |
| Patients with first diagnosis of HCC, n° (%)   | 36 (65.5)      |
| Patients with HCC relapse, n° (%)             | 19 (34.5)      |
| Patients with a single HCC, n° (%)            | 27 (49.1)      |
| Patients with multiple HCC, n° (%)            | 28 (50.9)      |
| Patients with portal thrombosis, n° (%)       | 3 (5.4)        |
| BCLC score, n° (%) of patients with           | 55             |
| - A                                           | 47 (85.4)      |
| - B                                           | 5 (9.1)        |
| - C                                           | 3 (5.5)        |
Evaluation of miR-125a target genes

In a recent study, we have evaluated the ability of miR-125a to interfere with the expression of known target genes in hepatocellular carcinoma HepG2 cells. The microRNA was transfected into the cells and the expression levels of ERBB2, ERBB3, MMP11, Zbtb7a, SIRT7, and VEGF-A were measured 48 h later. This analysis showed significant downregulation of MMP11, Zbtb7a and SIRT7 whereas the other targets were unaffected [22]. In the same study, we found that c-Raf is a direct target of miR-125a. Based on these data collected in vitro, we measured the expression level of MMP11, Zbtb7a, SIRT7 and c-Raf in tumor biopsies, focusing on those patients showing a downregulation of miR-125a of at least 2-fold. Comparison with the adjacent NC tissue revealed that MMP11, SIRT7 and c-Raf were upregulated in 71-83% of the patients with mean fold regulation values of 3, 2.2 and 1.7, respectively (Table 3). On the other hand, Zbtb7a didn’t show a significant upregulation.

DISCUSSION

MicroRNA-125a-5p, denominated lin-4 in nematodes, appeared early in evolution, no later than 550 millions of years ago. Today, it is present in all...
animals with bilateral symmetry and its nucleotide sequence is very well conserved, with an 11 nucleotide stretch encompassing the seed region that is identical in all species analyzed [24]. This microRNA plays a fundamental role in downregulating Lin-28 protein, thus promoting phase transitions in development and/or cell differentiation in nematodes, insects and mammals [36–39]. In mammalians, miR-125a appears to be expressed in most tissues, mainly targeting membrane receptors or intracellular signal transducers of mitogenic signals, thus limiting cell proliferation. Expression of this miRNA generally increases with cell differentiation whereas it is downregulated in several types of tumors, such as breast [25–27], lung [32, 33], ovarian [40], gastric [41], colon [42], and cervical [43] cancers, neuroblastoma [29], medulloblastoma [30], glioblastoma [31], and retinoblastoma [44]. Limited studies on the expression of miR-125a in HCC have also been performed. In 2013, Kim JK et al. used microarrays to analyze 16 samples of HCC of unknown etiology and compared the expression of the miRNA with 8 samples on non-matched liver tissue, showing a significant downregulation of miR-125a [34]. Similar results were obtained by Bi Q et al. that analyzed 80 samples of HCC, mostly from patients with chronic hepatitis B [35]. Then, our work is the first study conducted on a large cohort of well-characterized patients with chronic hepatitis C. It demonstrates a marked down-regulation of miR-125a in tumor tissue and a subsequent up-regulation of its oncogenic targets MMP11, SIRT7 and c-Raf. These data suggest an oncosuppressor effect of the microRNA on HCC of different etiologies, likely through the regulation of MMP11, c-Raf and SIRT7 expression. No correlation between the down-regulation of miR-125a and severity of HCC was observed, suggesting that the miRNA is mainly involved in the initiation of the oncogenic process. However, the majority of patients had an early stage of HCC, whereas this correlation should be evaluated in a larger sample of patients with HCC at different stages. The correlation between higher serum level of total bilirubin and higher down-regulation of miR-125a is intriguing. Recently, Han and colleagues evaluated the factors associated with the recurrence of HCC in 250 recipients of liver transplantation; they showed a correlation between lower serum values of total bilirubin in the donors and higher rate of HCC recurrence in the recipients, suggesting a protective role of bilirubin due to an anti-oxidant effect [45]. Thus, we may hypothesize that a higher down-regulation of miR-125a and a subsequent up-regulation of its targets may cause an activation of anti-oxidant factors, including serum bilirubin. However, this hypothesis should be confirmed in specific studies.

Besides their central role in control of cell proliferation and differentiation, microRNAs act as regulators of virus-host interactions [46, 47]. With regard to hepatotropic viruses, miR-125a has been shown to interfere with the expression of hepatitis B virus surface antigen [48–50] thus limiting viral replication [51]. It is not uncommon that a microRNA affects multiple cellular activities since a single miRNA can bind several mRNAs provided with the same target sequence. In the case of miR-125a, the antiproliferative activity toward hepatic cells and the antireplicative activity toward HBV are clearly due to inhibition of two different pathways but they may be functionally related. Since HBV has appeared late in evolution, infecting only mammals and birds, primary role of miR-125a is most likely fine tuning of cell proliferation. HBV may have then coopted this cellular miRNA to modulate its own replication, keeping it low

**Figure 3:** MicroRNA-125a expression in HCC from patients with viral or non-alcoholic steatotic hepatitis. Data are the mean ± SEM. * p < 0.05 and ** p < 0.00001 at Student’s t-test for comparison with NC tissue.
Table 2: Correlation between miRNA expression and demographic, biochemical, virological, and clinical characteristics of the patients

|                                | HCC vs. NC fold-regulation ≤ -2.13 | HCC vs. NC fold-regulation > -2.13 | p    |
|--------------------------------|-----------------------------------|-----------------------------------|------|
| Nº patients                    | 28                                | 27                                |      |
| Mean age (±SD)                 | 70.2 (5.6)                        | 70.3 (6.6)                        | 0.96 |
| Males, nº (%)                  | 14 (50.0)                         | 18 (66.7)                         | 0.21 |
| Alcohol abusers (> 30g/die), nº (%) | 0 (0.0)                          | 2 (7.4)                           | 0.14 |
| BMI (mean ± SD)                | 26.2 (2.8)                        | 27.6 (3.4)                        | 0.15 |
| Subjects with diabetes, nº (%) | 4 (14.3)                          | 3 (11.1)                          | 0.99 |
| AST/ULN (mean ± SD)            | 1.47 (0.9)                        | 1.61 (0.9)                        | 0.60 |
| ALT/ULN (mean ± SD)            | 1.45 (0.9)                        | 1.54 (0.9)                        | 0.72 |
| ALP/ULN (mean ± SD)            | 1.1 (0.3)                         | 1.2 (0.8)                         | 0.47 |
| Total bilirubin, mg/dl (mean ± SD) | 1.17 (0.6)                       | 0.78 (0.3)                        | 0.008|
| PT% (mean ± SD)                | 88.2 (12.6)                       | 90.3 (13.1)                       | 0.55 |
| α-fetoprotein, (mean ± SD)     | 119.9 (413.8)                     | 363.7 (941.4)                     | 0.27 |
| Anti-HCV-positive patients, nº (%) | 22 (78.6)                       | 19 (70.4)                         | 0.48 |
| - HCV-RNA-positive subjects, nº (%) | 18 (81.8)                      | 15 (78.9)                         | 0.81 |
| - HCV load, IU/mL (mean ± SD)  | 1.02 E+6 (1.53 E+6)              | 1.42 E+6 (1.87 E+6)              | 0.51 |
| - with HCV-genotype 1, nº (%)  | 17 (77.3)                         | 11 (57.9)                         | 0.18 |
| HBsAg-positive patients, nº (%) | 3 (10.7)                         | 7 (24.1)                          | 0.14 |
| - HBV-DNA-positive subjects, nº (%) | 1 (30.0)                       | 2 (28.6)                          | 0.88 |
| - HBV load, IU/mL (mean ± SD)  | 3.34 E+4                         | 3.06 E+2 (5.1 E+1)               | NA   |
| Patients with NASH, nº (%)     | 3 (10.7)                          | 1 (3.7)                           | 0.32 |
| Child Pugh score, nº (%) of patients with |                     |                                   |      |
| - A                            | 24 (85.7)                         | 25 (92.6)                         |      |
| - B                            | 4 (14.3)                          | 2 (7.4)                           |      |
| - C                            | 0 (0.0)                           | 0 (0)                             | 0.41 |
| Patients with first diagnosis of HCC, nº (%) | 19 (67.9)                      | 17 (63.0)                         |      |
| Patients with HCC relapse, nº (%) | 9 (32.1)                         | 10 (37.0)                         | 0.70 |

(Continued)
to escape the immune system and establish a persistent infection. It may also be speculated that HBV has become sensitive to miR-125a, among hundreds of other hepatic miRNAs, to coordinate its replication to the host cell proliferation.

Downregulation of microRNAs in cancer cells may be determined by genetic or epigenetic factors [52]. Chromosomal abnormalities, deletions, and mutation of promoter regions can reduce the expression level of miRNAs [53, 54]. It is also known that several miRNA genes are associated to CpG islands and are downregulated by DNA methylation [55]. With regard to miR-125a, a recent study has shown its downregulation in acute myeloid leukemic cells due to aberrant methylation of a CpG island located 3544 bp upstream of the mature miRNA sequence [56]. Further investigations aimed at the

| Patients with a single HCC, n° (%) | HCC vs. NC fold-regulation ≤ -2.13 | HCC vs. NC fold-regulation > -2.13 | p |
|----------------------------------|-------------------------------------|-------------------------------------|---|
| 17 (60.7)                        | 10 (37.0)                           |                                     |   |
| Patients with multiple HCC, n° (%)|                                     |                                     |   |
| 11 (39.3)                        |                                     | 17 (63.0)                           | 0.08 |
| Patients with portal thrombosis, n° (%)|                                     | 1 (3.6)                             | 2 (7.4) | 0.53 |
| BCLC score, n° (%) of patients with |                                     |                                     |   |
| - A                              | 25 (89.3)                           | 22 (81.5)                           |   |
| - B                              | 2 (7.1)                             | 3 (11.1)                            |   |
| - C                              | 1 (3.6)                             | 2 (7.4)                             | 0.4 |

Table 3: Expression levels of validated targets of miR-125a in hepatocellular carcinoma

| Etiology | Patient | MMP11 | SIRT7 | c-Raf | Zbtb7a |
|----------|---------|-------|-------|-------|--------|
| HBV      | 1       | n.d.  | 0.40  | 0.50  | 0.60   |
|          | 26      | 0.92  | 0.65  | 1.02  | 0.67   |
|          | 30      | 5.07  | 1.85  | 0.95  | 1.41   |
|          | 5       | 1.49  | 1.38  | 1.18  | 1.83   |
|          | 32      | 1.61  | 2.51  | 1.53  | 0.05   |
|          | 35      | 0.46  | 1.51  | 2.46  | 1.77   |
|          | 36      | 4.61  | 4.20  | 2.47  | 2.29   |
|          | 39      | n.d.  | 2.92  | 1.06  | 0.71   |
|          | 43      | 3.44  | 2.42  | 1.99  | 0.54   |
|          | 54      | 0.78  | 4.24  | 0.73  | 1.42   |
|          | 56      | 9.97  | 1.95  | 5.35  | 0.36   |
|          | 65      | 2.10  | 2.00  | 2.30  | 1.70   |
|          | 23      | 2.50  | n.d.  | 0.99  | 1.17   |
| NASH     | 49      | 3.37  | n.d.  | 1.53  | 0.70   |
|          | mean    | 3.03* | 2.17* | 1.72* | 1.09   |

Expression levels were evaluated by RT-qPCR in a subset of patients with a downregulation of miR-125a of at least 2-fold. Data are reported as fold regulation for comparison of hepatocellular carcinoma (HCC) tissue with matched adjacent non-tumor liver tissue (NC). N.d., not determined because of the limited amount of tissue. * p < 0.05 at Wilcoxon test.
identification of the promoter of the transcription unit of miR-125a will allow the comprehension of the molecular mechanisms governing its expression, eventually leading to treatments to restore its expression in tumor cells. Otherwise, vectors for the ectopic expression of miRNA mimics [57] may be used to boost the cellular reservoir of miR-125a. Finally, recent progress in cell transfection techniques has led to development of efficient formulations for therapeutic delivery of synthetic microRNAs based on cationic polymers or exosomes [58, 59]. These techniques have made the use of small RNAs in human therapy a promising therapeutic approach and several clinical trials are in progress [60].

**PATIENTS AND METHODS**

Patients

This study was planned as prospective with a progressive enrolment by the senior investigators of two participating Liver Units in Naples, southern Italy. The two centers participating to the study have cooperated in several investigations using the same clinical approach [61]. All consecutive patients who underwent a diagnostic liver biopsy for HCC at one of two participating Liver Units from June 2013 to May 2014 were enrolled. HCC was diagnosed in accordance with the EASL/EORTC criteria [62]. Each patient underwent a complete physical examination, full liver function tests and serology for HBsAg, anti-delta, anti-HIV and anti-HCV. The anti-HCV-positive patients were considered as having HCV infection. A diagnosis of NASH (non-alcoholic steatohepatitis) was made according to the AASLD/ACG/AGA guidelines [63]. Alcohol intake and other potential causes of liver disease were assessed. A consumption of alcohol exceeding 30 g per day for females and 40 g per day for males over at least the last 6 months was considered as alcohol abuse. None of the patients was anti-HIV positive.

The stage of HCC was assessed using the criteria proposed by the BCLC (Barcelona Clinic Liver Cancer) group [64]. For each patient, a HCC specimen and a non-neoplastic liver tissue sample (NC) were obtained by US-guided percutaneous liver biopsy using a needle Biomol®. For each patient, a HCC specimen and a non-neoplastic liver tissue sample (NC) were obtained by US-guided percutaneous liver biopsy using a needle Biomol®

**Sero-virological methods**

HBV serum markers (HBsAg, anti-HBs, anti-HBc) were sought using commercial immunoenzymatic assays (Abbott Laboratories, North Chicago, IL, USA). The anti-HCV antibody was detected using a 3rd generation commercial immunoenzymatic assay (Ortho Diagnostic Systems, Neckargemund, Germany). Liver biochemistry and routine analyses were performed by standard methods in a Cobas Modular 6,000 automated analyzer using c501 biochemistry modules (Roche Diagnostics Ltd, Rotkreuz, Switzerland). For HBsAg positive patients, serum HBV-DNA levels were determined by real-time PCR with a detection limit of 20 copies/mL, as previously described [66]. For anti-HCV positive patients, viral RNA was extracted from 140 μl of plasma samples using a microspin column (QIAamp RNA viral kit, Qiagen GmbH). HCV RNA was quantified by real-time PCR in a Light cycler 1.5 (Roche Diagnostics, Branchburg, NJ, USA), as reported [67]; the detection limit of this method is about 40 IU/mL of plasma. HCV genotypes were determined by the HCV genotype Lipa assay (Bayer, France) following the manufacturer’s instructions.

**Tissue RNA extraction and real-time qPCR analyses**

HCC and NC liver tissues were homogenized by TissueLyser (Qiagen GmbH, Hilden, Germany) at 30 Hz for 30 sec. Total RNA was then extracted by microspin columns (AllPrep DNA/RNA mini kit, Qiagen GmbH, Hilden, Germany) and quantitated spectrophotometrically with NanoDrop 2000c (ThermoScientific). MiR-125a was quantified along with RNU6B (reference gene) by RT-qPCR with TaqMan® miRNA assays from Applied Biosystems according to the manufacturer’s protocol. The expression levels of transcripts targeted by miR-125a were determined by RT-qPCR with iTaq™ Universal SYBR® Green Supermix (Bio-Rad). In particular, 200 ng of RNA were retrotranscribed by Transcriptor High Fidelity cDNA Synthesis Sample kit (Roche) using random examer primers; 1 μl of cDNA product was then used to amplify the target sequences along with GAPDH as reference. Primers were: GAPDH, 5′-GAAGGTGAAGGTCGGAGTC-3′ and 5′-GAAGATGGTGATGGGATTT-3′; SIRT7, 5′-GTGATGAGCAGAAGCTG-3′ and 5′-GGAACGCAGGAGTGACAGAC-3′; c-Raf, 5′-GGACAGCGCTAGCTGATG-3′ and 5′-GGACACGCAAGGTACACAGC-3′; e-Raf, 5′-GGAATGGAAGGGCTGTTGAGC-3′ and 5′-GGACAGCGCTAGCTGATG-3′; Zbtb7a, 5′-ACGAGTGGCACAATCTGCAAG-3′ and 5′-GGTCGATGGTCGGCGCAGC-3′; MPP11, 5′-TCGACTTTTTGGCTGTCG-3′ and 5′-CCATGGGTCT
CTAGCCTGAT-3’ [35]. The expression levels of miR-125a and its targeted transcripts were normalized to their respective reference genes by using the 2−ΔΔCt method.

**Statistical analysis**

Continuous variables were summarized as mean ± standard deviation, unless stated differently; categorical variables were expressed as absolute and relative frequencies. Differences in the mean values were evaluated by the Student’s t-test except for the expression levels of miR-125a targets that did not follow a normal distribution and were compared by the Wilcoxon test; the chi-squared test was used to compare categorical variables. A p value <0.05 was considered to be statistically significant.

**Abbreviations**

HCC, hepatocellular carcinoma; NC non-neoplastic liver tissue; miRNA, microRNA; miR-125a, human miR-125a-5p; SIRT7, sirtuin-7; VEGF-A, vascular endothelial growth factor A; MMP11, matrix metalloproteinase-11; HBV, hepatitis B virus; HCV, hepatitis C virus; NASH, non-alcoholic steatotic hepatitis.

**CONFLICTS OF INTEREST**

All authors declare no potential conflict of interest.

**GRANT SUPPORT**

This work was supported by Regione Campania (L5/2002) and in part by Fellowship program 2015.

**REFERENCES**

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136: E359-386.

2. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012; 379: 1245-1255.

3. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75: 843-854.

4. Ambros V. The functions of animal microRNAs. Nature. 2004; 431: 305-355.

5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-297.

6. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6: 857-866.

7. Rupaimoole R, Wu SY, Pradeep S, Ivan C, Pecot CV, Gharpure KM, Nagaraja AS, Armaiz-Pena GN, McGuire M, Zand B, Dalton HJ, Filant J, Miller JB, et al. LopezHypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat Commun. 2014; 5: 5202.

8. Kitagawa N, Ojima H, Shirakihara T, Shimizu H, Kokubu A, Urushidate T, Totoki Y, Kosuge T, Miyagawa S, Shibata T. Downregulation of the microRNA biogenesis components and its association with poor prognosis in hepatocellular carcinoma. Cancer Sci. 2013; 104: 543-551.

9. Foulkes WD, Priest JR, Duchaine TF. Dicer1: mutations, microRNAs and mechanisms. Nat Rev Cancer. 2014; 14: 662-672.

10. Potenza N, Papa U, Scaruffi P, Mosca N, Tonini GP, Russo A. A novel splice variant of the human dicer gene is expressed in neuroblastoma cells. FEBS Lett. 2010; 584: 3452-3457.

11. Kawase-Koga Y, Otaegi G, Sun T. Different timings of Dicer deletion affect neurogenesis and gliogenesis in the developing mouse central nervous system. Dev Dyn. 2009; 238: 2800-2812.

12. O’Rourke JR, Georges SA, Seay HR, Tapscott SJ, McManus MT, Goldhamer DJ, Swanson MS, Harfe BD. Essential role for Dicer during skeletal muscle development. Dev Biol. 2007; 311: 359-368.

13. Potenza N, Papa U, Russo A. Differential expression of Dicer and Argonaute genes during the differentiation of human neuroblastoma cells. Cell Biol Int. 2009; 33: 734-738.

14. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, Croce CM. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA. 2006; 103: 7024-7029.

15. Negrini M, Ferracin M, Sabbioni S, Croce CM. MicroRNAs in human cancer: from research to therapy. J Cell Sci. 2007; 120: 1833-1840.

16. Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol. 2014; 9: 287-314.

17. Negrini M, Gramantieri L, Sabbioni S, Croce CM. microRNA involvement in hepatocellular carcinoma. Anticancer Agents Med Chem. 2011; 11: 500-521.

18. Callegari E, Elamin BK, Sabbioni S, Gramantieri L, Negrini M. Role of microRNAs in hepatocellular carcinoma: a clinical perspective. OncoTargets Ther. 2013; 6: 1167-1178.

19. Ghidini M, Braconi C. Non-coding RNAs in primary liver cancer. Front Med. 2015; 2: 36

20. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006; 66: 11851-11858.

21. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner
22. Potenza N, Mosca N, Zappavigna S, Castiello F, Panella M, Ferri C, Vanacore D, Giordano A, Stiuso P, Caraglia M and Russo A. MicroRNA-125a-5p is a Downstream Effector of Sorafenib in its Antiproliferative Activity Toward Human Hepatocellular Carcinoma Cells. J Cell Physiol. 2016 Dec 16. doi: 10.1002/jcp.25744. [Epub ahead of print]

23. Stiuso P, Potenza N, Lombardi A, Ferrandino I, Monaco A, Zappavigna S, Vanacore D, Mosca N, Castiello F, Porto S, Addeo R, Prete SD, De Vita F, et al. MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib. Mol Ther Nucleic Acids. 2015; 4: e233.

24. Potenza N, Russo A. Biogenesis, evolution and functional targets of microRNA-125a. Mol Genet Genomics. 2013; 288: 381-389.

25. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem. 2007; 282: 1479-1486.

26. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginztinger D, Getts R, Haqq C. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer. 2006; 5: 24.

27. Guo X, Wu Y, Hartley RS. MicroRNA-125a represses cell growth targeting HuR in breast cancer. RNA Biol. 2009; 6: 575-583.

28. Li W, Duan R, Kooy F, Sherman SL, Zhou W, Jin P. Germline mutation of microRNA-125a is associated with breast cancer. J Med Genet. 2009; 46: 358-360.

29. Laneve P, Di Marcotullio L, Gioia U, Fiori ME, Ferretti E, Gulino A, Bozzoni I, Caffarelli E. The interplay between microRNAs and the neurotrophin receptor tropomyosin-related kinase C controls proliferation of human neuroblastoma cells. Proc Natl Acad Sci USA. 2007; 104: 7957-7962.

30. Ferretti E, de Smaele E, Po A, Di Marcotullio L, Tosi E, Espinola MS, Di Rocco C, Riccardi R, Giangaspero F, Farcomeni A, Nofroni I, Laneve P, Gioia U, et al. MicroRNA profiling in human medulloblastoma. Int J Cancer. 2009; 124: 568-577.

31. Cortez MA, Nicoloso MS, Shimizu M, Rossi S, Gopisetty G, Molina JR, Carlotti C Jr, Tirapelli D, Neder L, Brassesco MS, Scrideli CA, Tone LG, Georgescu MM, et al. miR-29b and miR-125a regulate podoplanin and suppress invasion in glioblastoma. Genes Chromosomes Cancer. 2010; 49: 981-990.

32. Wang G, Mao W, Zheng S, Ye J. Epidermal growth factor receptor-regulated miR-125a-5p-a metastatic inhibitor of lung cancer. FEBS J. 2009; 276: 5571-5578.

33. Hojo N, Tatsumi N, Moriguchi N, Matsumura A, Morimoto S, Nakata J, Fujiki F, Nishida S, Nakajima H, Tsuboi A, Oka Y, Hosen N, Hayashi S, et al. A Zbtb7a proto-oncogene as a novel target for miR-125a. Mol Carcinog. 2016; 55: 2001-2009.

34. Kim JK, Noh JH, Jung KH, Eun JW, Bae HJ, Kim MG, Chang YG, Shen Q, Park WS, Lee JY, Borlak J, Nam SW. Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology. 2013; 57: 1055-1067.

35. Bi Q, Tang S, Xia L, Du R, Fan R, Gao L, Jin J, Liang S, Chen Z, Xu G, Nie Y, Wu K, Liu J, et al. Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. PLoS One. 2012; 7: e40169.

36. Moss EG, Lee RC, Ambros V. The cold shock domain protein LIN-28 controls developmental timing in C. elegans and is regulated by the lin-4 RNA. Cell. 1997; 88: 637-646.

37. Caygill EE, Johnston LA. Temporal regulation of metamorphic processes in Drosophila by the let-7 and miR-125 heterochronic microRNAs. Curr Biol. 2008; 18: 943-950.

38. Wu L, Belasco JG. Micro-RNA regulation of the mammalian lin-28 gene during neuronal differentiation of embryonal carcinoma cells. Mol Cell Biol. 2005; 25: 9198-9208.

39. Takashima Y, Terada M, Udono M, Miura S, Yamamoto J, Suzuki A. Suppression of lethal-7b and miR-125a/b Maturation by Lin28b Enables Maintenance of Stem Cell Properties in Hepatoblasts. Hepatology. 2016; 64: 245-260.

40. Lee M, Kim EJ, Jeon MJ. MicroRNAs 125a and 125b inhibit ovarian cancer cells through post-transcriptional inactivation of EIF4EBP1. Oncotarget. 2016; 7: 8726-8742. doi: 10.18632/oncotarget.6474.

41. Xu Y, Huang Z, Liu Y. Reduced miR-125a-5p expression is associated with gastric carcinogenesis through the targeting of E2F3. Mol Med Rep. 2014; 10: 2601-2608.

42. Tong Z, Liu N, Lin L, Guo X, Yang D, Zhang Q. miR-125a-5p inhibits cell proliferation and induces apoptosis in colon cancer via targeting BCL2, BCL2L12 and MCL1. Biomed Pharmacother. 2015; 75: 129-136.

43. Fan Z, Cui H, Xu X, Lin Z, Zhang X, Kang L, Han B, Meng J, Yan Z, Yan X, Jiao S. MiR-125a suppresses tumor growth, invasion and metastasis in cervical cancer by targeting STAT3. Oncotarget. 2015; 6: 25266-25280. doi: 10.18632/oncotarget.6474.

44. Zhang Y, Xue C, Zhu X, Zhu X, Xian H, Huang Z. Suppression of microRNA-125a-5p upregulates the TAZ-EGFR signaling pathway and promotes retinoblastoma proliferation. Cell Signal. 2016; 28: 850-860.

45. Han S, Yang JD, Sinn DH, Ko JS, Kim JM, Shin JC, Son HJ, Gwak MS, Joh JW and Kim GS. Higher Bilirubin Properties in Hepatoblasts. Hepatology. 2001-2009.

46. Umbach JL, Cullen BR. The role of RNAi and microRNAs in animal virus replication and antiviral immunity. Genes Dev. 2009; 23: 1151-1164.
47. Russo A, Potenza N. Antiviral effects of human microRNAs and conservation of their target sites. FEBS Lett. 2011; 585: 2551-2555.

48. Potenza N, Papa U, Mosca N, Zerbini F, Nobile V, Russo A. Human microRNA hsa-miR-125a-5p interferes with expression of hepatitis B virus surface antigen. Nucleic Acids Res. 2011; 39: 5157-5163.

49. Coppola N, Potenza N, Pisaturo M, Mosca N, Tonziello G, Signoriello G, Messina V, Sagnelli C, Russo A, Sagnelli V. Liver microRNA hsa-miR-125a-5p in HBV chronic infection: correlation with HBV replication and disease progression. PLoS One. 2014; 8: e65336.

50. Mosca N, Castiello F, Coppola N, Trotta MC, Sagnelli C, Pisaturo M, Sagnelli E, Russo A and Potenza N. Functional interplay between hepatitis B virus X protein and human miR-125a in HBV infection. Biochem Biophys Res Commun. 2014; 449: 141-145.

51. Park SO, Kumar M, Gupta S. TGF-β and iron differently alter HBV replication in human hepatocytes through TGF-β/BMP signaling and cellular microRNA expression. PLoS One. 2012; 7: e39276.

52. Iorio MV, Croce CM. Causes and consequences of microRNA dysregulation. Cancer J. 2012; 18: 215-222.

53. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002; 99:15524-15529.

54. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004; 101: 2999-3004.

55. Weber B, Stresemann C, Brueckner B and Lyko F. Methylation of human microRNA genes in normal and neoplastic cells. Cell Cycle. 2007; 6: 1001-1005.

56. Ulkin ML, Peterson S, Yang X, Driscoll H, Duarte C and Sathyanarayana P. miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia. Leuk Res. 2014; 38: 402-410.

57. Liu YP, Berkhourt B. Design of lentivirally expressed siRNAs. Methods Mol Biol. 2013; 942: 233-257.

58. Wagner E. Polymers for nucleic acid transfer—an overview. Adv Genet. 2014; 88: 231-261.

59. Tominaga N, Yoshioka Y, Ochiya T. A novel platform for cancer therapy using extracellular vesicles. Adv Drug Deliv. 2015; 95: 50-55.

60. Barata P, Sood AK, Hong DS. RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. Cancer Treat Rev. 2016; 50: 35-47.

61. Coppola N, Onorato L, Iodice V, Starace M, Minichini C, Farella N, Liore R, Filippini P, Sagnelli E, de Stefano G. Occult HBV infection in HBsAg-negative patients: a virological and clinical study. Oncotarget. 2016; 7:62706-62714. doi: 10.18632/oncotarget.10909.

62. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56: 908-943.

63. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ; American Gastroenterological Association; American Association for the Study of Liver Diseases; American College of Gastroenterology. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012; 142: 1592-1609.

64. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19: 329-338.

65. Coppola N, Pisapia R, Tonziello G, Martini S, Imparato M, Piai G, Stanzione M, Sagnelli C, Filippini P, Piccinino F, Sagnelli E. Virological pattern in plasma, peripheral blood mononuclear cells and liver tissue and clinical outcome in chronic hepatitis B and C virus coinfection. Antivir Ther. 2008; 13: 307-318.

66. Filippini P, Coppola N, Pisapia R, Martini S, Marrocco C, Di Martino F, Sagnelli C, Filippini A, Sagnelli E. Virological and clinical aspects of HBV-HCV coinfection in HIV positive patients. J Med Virol. 2007; 79: 1679-1685.

67. Coppola N, Zamponi R, Cirillo G, Stanzione M, Macera M, Boehm A, Grandone A, Pisaturo M, Marrone A, Adinolfi LE, Sagnelli E, Miraglia Del Giudice E. TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism. Liver Int. 2015; 35: 1959-1963.